2. Metabolic Enzyme/Protease Anti-infection Apoptosis
  3. Endogenous Metabolite Parasite Apoptosis
  4. Linolelaidic acid

Linolelaidic acid  (Synonyms: Linoelaidic acid)

Cat. No.: HY-W071746 Purity: 99.52%
SDS COA Handling Instructions

Molarity Calculator

Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections.

For research use only. We do not sell to patients.

Linolelaidic acid Chemical Structure

Linolelaidic acid Chemical Structure

CAS No. : 506-21-8

Size Price Stock Quantity
50 mg USD 30 In-stock
100 mg USD 50 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Linolelaidic acid Related Antibodies

Top Publications Citing Use of Products

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections[1][2][3].

In Vitro

Linolenic Acid shows inhibitory activity against P. falciparum strains D10 (the chloroquine sensitive strain) and Dd2 (the chloroquine resistant strain), with IC50 values of 4.12 μg/mL and 5.04 μg/mL, respectively[2].
Linolelaidic acid (50 μM, 24 h) induces apoptosis, cell cycle arrest andinflammation in human umbilicalvein endothelial cells through lipid rafts[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Linolelaidic acid Related Antibodies

Cell Viability Assay[3]

Cell Line: Human umbilicalvein endothelial cells (HUVECs) (Methyl-β-cyclodextrin (HY-101461)-induced lipid raft disruption model)
Concentration: 50 μM
Incubation Time: 24 h
Result: Resulted in a significant decrease in cell viability.

Apoptosis Analysis[3]

Cell Line: Human umbilicalvein endothelial cells (HUVECs) (Methyl-β-cyclodextrin (HY-101461)-induced lipid raft disruption model)
Concentration: 50 μM
Incubation Time: 24 h
Result: Resulted in a significant increase in the number of apoptotic cells and the cell population in the G1 phase.

Western Blot Analysis[3]

Cell Line: Human umbilicalvein endothelial cells (HUVECs) (Methyl-β-cyclodextrin (HY-101461)-induced lipid raft disruption model)
Concentration: 50 μM
Incubation Time: 24 h
Result: Led to a significant increase in the expression levels of pro-apoptotic proteins (caspase-3, -8, Bax, p53) and inflammatory factors (vascular cell adhesion molecule-1, intercellular adhesion molecule, E-selectin, and nitric oxide), while the expression level of the anti-apoptotic protein Bcl-2 was significantly decreased.
In Vivo

Linolenic Acid (10 mg/kg, p.o., once daily for 4 days) shows anti-parasitic activity in the P. berghei (ANKA) strain-induced malaria C57BL/6 mouse model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: P. berghei (ANKA) strain-induced malaria C57BL/6 mice model (7-to-10-week old)[3]
Dosage: 10 mg/kg
Administration: Oral gavage (p.o.), once daily for 4 days
Result: Inhibited the growth of P. berghei by 70%.
Animal Model: High-fat diet-fed streptozotocin (HFD-STZ) rat model[2]
Dosage: 500 μg/kg
Administration: Oral gavage (p.o.), once daily for 4 weeks, 30 min myocardial ischemia followed by 4 or 6 h reperfusion after 4 weeks
Result: Significantly improved the instantaneous first derivation of left ventricle pressure, reduced infarct size, plasma creatine kinase and lactate dehydrogenase activities, and apotosis at the end of reperfusion in HFD-STZ diabetic rats.
Not only significantly reduced tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) concentrations but reduced the increase in superoxide production and malonaldialdehyde formation and simultaneously enhanced the antioxidant capacity in the diabetic hearts.
Increased myocardial PI3K expression and Akt phosphorylation in diabetic but not normal rats.
Molecular Weight

280.45

Formula

C18H32O2
CAS No.
Appearance

Liquid (Density: 0.89 g/cm3)

Color

Colorless to light yellow

SMILES

CCCCC/C=C/C/C=C/CCCCCCCC(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (445.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.5657 mL 17.8285 mL 35.6570 mL
5 mM 0.7131 mL 3.5657 mL 7.1314 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.52%

SDS (393 KB)

COA (239 KB) HNMR (268 KB) RP-HPLC (207 KB) MS (70 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.5657 mL 17.8285 mL 35.6570 mL 89.1424 mL
5 mM 0.7131 mL 3.5657 mL 7.1314 mL 17.8285 mL
10 mM 0.3566 mL 1.7828 mL 3.5657 mL 8.9142 mL
15 mM 0.2377 mL 1.1886 mL 2.3771 mL 5.9428 mL
20 mM 0.1783 mL 0.8914 mL 1.7828 mL 4.4571 mL
25 mM 0.1426 mL 0.7131 mL 1.4263 mL 3.5657 mL
30 mM 0.1189 mL 0.5943 mL 1.1886 mL 2.9714 mL
40 mM 0.0891 mL 0.4457 mL 0.8914 mL 2.2286 mL
50 mM 0.0713 mL 0.3566 mL 0.7131 mL 1.7828 mL
60 mM 0.0594 mL 0.2971 mL 0.5943 mL 1.4857 mL
80 mM 0.0446 mL 0.2229 mL 0.4457 mL 1.1143 mL
100 mM 0.0357 mL 0.1783 mL 0.3566 mL 0.8914 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Linolelaidic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Linolelaidic acid506-21-8Linoelaidic acidEndogenous MetaboliteParasiteApoptosisHuman umbilicalvein endothelial cells (HUVECs)P. berghei (ANKA) strain-induced malaria C57BL/6 mice modelAnti-inflammatory activityAntioxidant stress-reducing activityAnti-parasitic activityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Linolelaidic acid
Cat. No.:
HY-W071746
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.